WO2000067697A3 - Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules - Google Patents

Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules Download PDF

Info

Publication number
WO2000067697A3
WO2000067697A3 PCT/FR2000/001259 FR0001259W WO0067697A3 WO 2000067697 A3 WO2000067697 A3 WO 2000067697A3 FR 0001259 W FR0001259 W FR 0001259W WO 0067697 A3 WO0067697 A3 WO 0067697A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
cells
antibody conjugate
delivering
foreign
Prior art date
Application number
PCT/FR2000/001259
Other languages
English (en)
Other versions
WO2000067697A2 (fr
Inventor
Francois Hirsch
Antoine Durrbach
Original Assignee
Centre Nat Rech Scient
Francois Hirsch
Antoine Durrbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Francois Hirsch, Antoine Durrbach filed Critical Centre Nat Rech Scient
Priority to EP00925426A priority Critical patent/EP1175498A2/fr
Priority to AU44152/00A priority patent/AU4415200A/en
Priority to CA002373851A priority patent/CA2373851A1/fr
Priority to JP2000616728A priority patent/JP2002543810A/ja
Priority to IL14639900A priority patent/IL146399A0/xx
Publication of WO2000067697A2 publication Critical patent/WO2000067697A2/fr
Publication of WO2000067697A3 publication Critical patent/WO2000067697A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne les techniques relatives à l'introduction d'acide nucléique étranger dans des cellules. Plus particulièrement, la présente invention concerne un conjugué ADN/anticorps permettant l'expression efficace d'ADN étranger sous forme protéique dans des cellules cibles in vivo ou in vitro.
PCT/FR2000/001259 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules WO2000067697A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00925426A EP1175498A2 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
AU44152/00A AU4415200A (en) 1999-05-10 2000-05-10 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
CA002373851A CA2373851A1 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
JP2000616728A JP2002543810A (ja) 1999-05-10 2000-05-10 外来性核酸を細胞に送達するための核酸−抗体複合体
IL14639900A IL146399A0 (en) 1999-05-10 2000-05-10 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/05943 1999-05-10
FR9905943A FR2793414B1 (fr) 1999-05-10 1999-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Publications (2)

Publication Number Publication Date
WO2000067697A2 WO2000067697A2 (fr) 2000-11-16
WO2000067697A3 true WO2000067697A3 (fr) 2001-06-28

Family

ID=9545418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001259 WO2000067697A2 (fr) 1999-05-10 2000-05-10 Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules

Country Status (7)

Country Link
EP (1) EP1175498A2 (fr)
JP (1) JP2002543810A (fr)
AU (1) AU4415200A (fr)
CA (1) CA2373851A1 (fr)
FR (1) FR2793414B1 (fr)
IL (1) IL146399A0 (fr)
WO (1) WO2000067697A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517793A (ja) * 2003-01-31 2006-08-03 ノバルティス アクチエンゲゼルシャフト スクリーニングアッセイ
JP4521519B2 (ja) * 2003-05-26 2010-08-11 学校法人慶應義塾 部分ヒストンテイル型イムノポーター
FR2958645B1 (fr) * 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
US10540907B2 (en) 2014-07-31 2020-01-21 Intelligent Technologies International, Inc. Biometric identification headpiece system for test taking
US10410535B2 (en) 2014-08-22 2019-09-10 Intelligent Technologies International, Inc. Secure testing device
CN106662746B (zh) 2014-08-22 2020-10-23 国际智能技术公司 安全考试设备、***和方法
WO2016073202A1 (fr) 2014-11-04 2016-05-12 Intelligent Technologies International, Inc. Carte intelligente
CN108530540B (zh) * 2018-03-30 2021-06-15 华南农业大学 抗亚精胺单克隆抗体杂交瘤细胞株4e4及其单克隆抗体和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (fr) * 1987-05-06 1988-11-17 Egbert Oosterwijk Anticorps monoclonaux contre le carcinome des cellules renales
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1994004696A1 (fr) * 1992-08-25 1994-03-03 Miles Inc. Apport nucleaire de macromolecules facilite par un signal de translocation
WO1994013325A2 (fr) * 1992-12-15 1994-06-23 Microprobe Corporation Sequences de liaison peptidiques pour l'amelioration de l'apport d'oligonucleotides
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
WO1995021195A1 (fr) * 1994-02-07 1995-08-10 Research Development Foundation Vecteur non viral
WO1996013599A1 (fr) * 1994-11-01 1996-05-09 Winfried Wels Systeme de transfert de l'acide nucleique
WO1998002564A1 (fr) * 1996-07-12 1998-01-22 The John P. Robarts Research Institute Vecteur hybride de virus herpetique/virus de epstein-barr
WO1998047538A2 (fr) * 1997-04-23 1998-10-29 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Colorants de synthese labiles aux acides et clivables par voie enzymatique pour le diagnostic avec de la lumiere dans le proche infrarouge et pour l'usage therapeutique
WO1998056425A1 (fr) * 1997-06-11 1998-12-17 The School Of Pharmacy, University Of London Compositions pharmaceutiques contenant des conjugues anticorps-enzymes combines a des promedicaments

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1988008854A1 (fr) * 1987-05-06 1988-11-17 Egbert Oosterwijk Anticorps monoclonaux contre le carcinome des cellules renales
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
WO1994004696A1 (fr) * 1992-08-25 1994-03-03 Miles Inc. Apport nucleaire de macromolecules facilite par un signal de translocation
WO1994013325A2 (fr) * 1992-12-15 1994-06-23 Microprobe Corporation Sequences de liaison peptidiques pour l'amelioration de l'apport d'oligonucleotides
WO1995021195A1 (fr) * 1994-02-07 1995-08-10 Research Development Foundation Vecteur non viral
WO1996013599A1 (fr) * 1994-11-01 1996-05-09 Winfried Wels Systeme de transfert de l'acide nucleique
WO1998002564A1 (fr) * 1996-07-12 1998-01-22 The John P. Robarts Research Institute Vecteur hybride de virus herpetique/virus de epstein-barr
WO1998047538A2 (fr) * 1997-04-23 1998-10-29 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Colorants de synthese labiles aux acides et clivables par voie enzymatique pour le diagnostic avec de la lumiere dans le proche infrarouge et pour l'usage therapeutique
WO1998056425A1 (fr) * 1997-06-11 1998-12-17 The School Of Pharmacy, University Of London Compositions pharmaceutiques contenant des conjugues anticorps-enzymes combines a des promedicaments

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL PHARMACOLOGY, vol. 40, no. 2, 1990, pages 253 - 264, ISSN: 0006-2952 *
BIOCHEMISTRY AND CELL BIOLOGY, vol. 73, no. 11-12, 1995, pages 949 - 958, ISSN: 0829-8211 *
CHAKRABARTI, M. ET AL: "Transfer of DNA into lymphoma cells by DNA-bound to T101- biotinylated -avidin- polylysine antibody complex.", JOURNAL OF NUCLEAR MEDICINE, (1996) VOL. 37, NO. 5 SUPPL., PP. 62P. MEETING INFO.: 43RD ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE DENVER, COLORADO, USA JUNE 3-5, 1996, XP002133111 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, HUCKETT B ET AL: "EVIDENCE FOR TARGETED GENE TRANSFER BY RECEPTOR-MEDIATED ENDOCYTOSIS STABLE EXPRESSION FOLLOWING INSULIN-DIRECTED ENTRY OF NEO INTO HEPG2 CELLS", XP002155196, Database accession no. PREV199090077976 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, TRAUT ROBERT R ET AL: "Location and domain structure of Escherichia coli ribosomal protein L7/L12: Site specific cysteine cross-linking and attachment of fluorescent probes.", XP002155195, Database accession no. PREV199698797154 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; GUY J ET AL: "Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy.", XP002133112, retrieved from STN Database accession no. 96031841 *
FOMINAYA J ET AL: "Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 MAY 3) 271 (18) 10560-8., XP002133110 *
MOLECULAR BIOTECHNOLOGY, (1995 JUN) 3 (3) 237-48. REF: 60 *
PONCET ET AL: "ANTIFECTION: AN ANTIBODY-MEDIATED METHOD TO INTRODUCE GENES INTO LYMPHOID CELLS IN VITRO AND IN VIVO", GENE THERAPY, vol. 3, 1996, pages 731 - 738, XP000877306 *

Also Published As

Publication number Publication date
WO2000067697A2 (fr) 2000-11-16
IL146399A0 (en) 2002-07-25
CA2373851A1 (fr) 2000-11-16
FR2793414B1 (fr) 2003-05-23
FR2793414A1 (fr) 2000-11-17
JP2002543810A (ja) 2002-12-24
AU4415200A (en) 2000-11-21
EP1175498A2 (fr) 2002-01-30

Similar Documents

Publication Publication Date Title
WO2003020949A3 (fr) Produits de recombinaison cibles d'acides nucleiques et utilisations en rapport avec lesdits produits
EP1549352A4 (fr) Procedes d'administration d'acides nucleiques
WO2001075087A3 (fr) Variantes de lasubtilisine
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
WO2001062794A3 (fr) Nouveaux canaux calciques humains 18607
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
WO2003093469A3 (fr) Procedes d'administration de molecules d'acides nucleiques dans des cellules et evaluation associee
EP1775345A3 (fr) Constructions de vecteurs
AU1339701A (en) Anti-cancer nucleic acid and protein targets
WO2002006457A3 (fr) Genes de lipase
WO2001070777A3 (fr) Genes de cotyledon2 feuillus et leurs utilisations
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2003052117A3 (fr) Procedes et produits relatifs a la transfection non virale
WO2000067697A3 (fr) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
WO2002029057A3 (fr) 32144, nouveau membre de la famille des amides hydrolases d'acide gras humaines
CA2441535A1 (fr) Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport
WO2001092493A3 (fr) Nouvelles aminopeptidases humaines 21956 et 25856, et utilisations
WO2004029075A3 (fr) Acides nucleiques de peptides a recaptage et distribution dans les tissus ameliores
AU2438501A (en) Expression of proteins from amplified, immobilized nucleic acids
WO2002000857A3 (fr) Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
WO2000011168A3 (fr) Genes regulant les cellules souche hematopoietiques et utilisation de ces genes
WO2001079473A3 (fr) Nouveau membre de la famille de la prolyl oligopeptidase humaine, appele 21953, et ses utilisations
WO2000053759A8 (fr) Expression de l'alpha-fetoproteine humaine dans des cellules mammiferes
WO2002024898A3 (fr) Nouvelle lipase humaine 47647 et utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2000925426

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2373851

Country of ref document: CA

Ref country code: CA

Ref document number: 2373851

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616728

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09926493

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000925426

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000925426

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)